Market research
H2K2.F XTL Biopharmaceuticals Ltd
F EUR Healthcare
Latest close
—
—
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 1M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.73
Community
Investor discussion
1 comment
Sign in to join the H2K2.F discussion.
5 years, 5 months ago
XTL Biopharmaceuticals Ltd is currently in a long term uptrend where the price is trading 23.0% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
XTL Biopharmaceuticals Ltd's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 118.5% to $205K since the same quarter in the previous year.
Based on the above factors, XTL Biopharmaceuticals Ltd gets an overall score of 3/5.